EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment

F S Sinkeler iD, I J E Kouijzer, N G L Jager iD, J Ten Oever iD, E Leegwater, J Gisolf, D Reuling, Z M Spoel, M P M Hensgens, R J Brüggemann iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag304 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von F S Sinkeler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Acute Kidney Injury, Anti-Bacterial Agents, Bacteremia, Staphylococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Staphylococcus aureus bacteraemia (SAB) is associated with high mortality and frequent complications, including acute kidney injury (AKI). Although flucloxacillin has been associated with higher AKI rates than cefazolin, the clinical characteristics of AKI, including severity, timing, recovery and the potential influence of dosing, remain unclear.

Methods

We conducted a retrospective multicentre cohort study across three hospitals in the Netherlands, including adults with SAB treated with cefazolin or flucloxacillin. AKI incidence and severity were compared using adjusted regression analyses. Time-to-event and cumulative incidence analyses were used to evaluate AKI timing and renal recovery. Among flucloxacillin-treated patients, the association between initial dose and AKI was evaluated.

Results

Among 1408 patients, 483 (34.3%) developed AKI. Most AKI episodes occurred early after index blood culture (median 1.3 days), and recovery within 30 days decreased with increasing AKI severity (81.7% in Stage 1 versus 50.5% in Stage 3). AKI occurred more frequently among patients treated with flucloxacillin than cefazolin (466/1324 [35.2%] versus 17/84 [20.2%], P = 0.004). After multivariable adjustment, flucloxacillin remained associated with higher AKI risk (adjusted OR 2.37, 95% CI 1.30–4.55). Among patients with AKI, severity distribution did not differ between treatments (P = 0.599). Initial flucloxacillin dose was not associated with AKI occurrence, timing or severity.

Conclusions

Flucloxacillin was associated with increased AKI risk compared with cefazolin, with most AKI episodes occurring early after index blood culture and recovery decreasing with increasing AKI severity. Lower flucloxacillin doses were not associated with reduced AKI risk, suggesting that dose reduction alone may not mitigate flucloxacillin-associated nephrotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryAnti-Bacterial AgentsBacteremiaStaphylococcal InfectionsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCefazolinFirst Generation CephalosporinsFloxacillinIncidenceNetherlandsRetrospective StudiesStaphylococcus aureus

Substanzen

Anti-Bacterial AgentsCefazolinFirst Generation CephalosporinsFloxacillin

Autor:innen und Institutionen

  • Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Internal Medicine and Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
  • Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: F S Sinkeler, N G L Jager, J Ten Oever, R J Brüggemann

Förderung

  • ZonMw

Zitieren

APA

Sinkeler, F. S., Kouijzer, I. J. E., Jager, N. G. L., Ten Oever, J., Leegwater, E., Gisolf, J., Reuling, D., Spoel, Z. M., Hensgens, M. P. M., & Brüggemann, R. J. (2026). Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag304

Vancouver

Sinkeler FS, Kouijzer IJE, Jager NGL, Ten Oever J, Leegwater E, Gisolf J, et al. Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag304

BibTeX
@article{Sinkeler2026,
  author = {Sinkeler, F S and Kouijzer, I J E and Jager, N G L and Ten Oever, J and Leegwater, E and Gisolf, J and Reuling, D and Spoel, Z M and Hensgens, M P M and Brüggemann, R J},
  title = {Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag304}
}
Kostenlos starten →